@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix sct: <http://snomed.info/id/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<https://www.vision-zero-oncology.de/fhir/ResearchStudy/ExampleStudyRAAINBOW> a fhir:ResearchStudy ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "ExampleStudyRAAINBOW"] ; # 
  fhir:meta [
     fhir:profile ( [
       fhir:v "https://www.vision-zero-oncology.de/fhir/StructureDefinition/clinical-study"^^xsd:anyURI ;
       fhir:link <https://www.vision-zero-oncology.de/fhir/StructureDefinition/clinical-study>
     ] )
  ] ; # 
  fhir:text [
     fhir:status [ fhir:v "generated" ] ;
     fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: ResearchStudy</b><a name=\"ExampleStudyRAAINBOW\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource ResearchStudy &quot;ExampleStudyRAAINBOW&quot; </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-clinical-study.html\">Profile Clinical Study</a></p></div><p><b>identifier</b>: id: NCT03240627</p><p><b>title</b>: Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata.</p><p><b>status</b>: completed</p><p><b>primaryPurposeType</b>: Treatment <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-prim-purp-type.html\">ResearchStudyPrimaryPurposeType</a>#treatment)</span></p><p><b>phase</b>: Phase 2/Phase 3 <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-phase.html\">ResearchStudyPhase</a>#phase-2-phase-3)</span></p><p><b>category</b>: Interventional Study <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C98388)</span>, Randomized Controlled Clinical Trial <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C46079)</span>, Double Blind Study <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C15228)</span>, Unequal Randomization <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C142743)</span></p><p><b>focus</b>: Pharmacologic Substance <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C1909)</span></p><p><b>condition</b>: Alopecia areata (disorder) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#68225006)</span></p><p><b>location</b>: Germany <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-ISO3166Part1.html\">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#DE)</span>, France <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-ISO3166Part1.html\">ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code</a>#FR)</span></p><p><b>period</b>: 2018-03-01 --&gt; 2022-03-17</p><p><b>principalInvestigator</b>: <a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Practitioner/example\">Practitioner/example</a></p><p><b>site</b>: </p><ul><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Charite-dermatology\">Organization/Charite-dermatology</a></li><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Sabouraud-Center\">Organization/Sabouraud-Center</a></li><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/Diagnostic-consulting-center-XXIV-Sofia\">Organization/Diagnostic-consulting-center-XXIV-Sofia</a></li><li><a href=\"https://simplifier.net/resolve?scope=de.basisprofil.r4@1.4.0&amp;canonical=http://fhir.org/packages/de.basisprofil.r4/Organization/SC-Centrul-Medical-Sana-SRL\">Organization/SC-Centrul-Medical-Sana-SRL</a></li></ul><blockquote><p><b>arm</b></p><p><b>name</b>: Experimental: LH-8 cutaneous solution</p><p><b>type</b>: Investigational Arm <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C174266)</span></p><p><b>description</b>: LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp</p></blockquote><blockquote><p><b>arm</b></p><p><b>name</b>: Placebo Comparator: Placebo cutaneous solution</p><p><b>type</b>: Control Arm <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-v3-nciThesaurus.html\">NCI Thesaurus</a>#C174226)</span></p><p><b>description</b>: Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp</p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Relative change in scalp alopecia areata severity scores (SALT) from baseline value to be assessed after 24 weeks of treatment. [ Time Frame: 24 weeks treatment ] Visual assessment and global standardised scalp photographs for SALT evaluation.</p><p><b>type</b>: Primary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#primary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute change in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Adverse events [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: General physical examination findings, including irritation of eyes and skin [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Visual assessment and global standardised scalp photographs for SALT evaluation. [ Time Frame: After 12 and 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Evaluation of duration of treatment effect in responders, measured as relative SALT score changes from Visit 3 (end of treatment) after 12 weeks (Visit 4) and 24 weeks (Visit 5) of treatment-free period. (Visual assessment and global standardised scalp photographs for SALT evaluation.)</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of treatment effect on hair follicles in non-alopecic areas by quantifying the number of new alopecic areas. [ Time Frame: 24 weeks treatment ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of the rate of spontaneous hair regrowth. [ Time Frame: For 6-12 months ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Assessment of the rate of spontaneous hair regrowth in placebo treated subjects with alopecia areata active for 6-12 months compared to those with alopecia areata active for more than 12 months. (Visual assessment and global standardised scalp photographs for SALT evaluation).</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute and relative change from baseline in Children's Dermatology Life Quality Index (CDLQI) scores. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Change in percentage of subjects from baseline by the severity banding CDLQI scores. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Percentages of subjects by EuroQol Five Dimensions Youth Questionnaire (EQ-5D-Y) dimensions and levels at Visits 1-5. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Absolute and relative change of the EQ-Visual Analogue Scale (EQ-VAS) scores from baseline [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote><blockquote><p><b>objective</b></p><p><b>name</b>: Evaluation of the Paediatric Alopecia Areata Patient Benefit Index (PAAPBI) scores at Visits 1 to 5. [ Time Frame: 48 weeks ]</p><p><b>type</b>: Secondary <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://terminology.hl7.org/5.3.0/CodeSystem-research-study-objective-type.html\">ResearchStudyObjectiveType</a>#secondary)</span></p></blockquote></div>"
  ] ; # 
  fhir:identifier ( [
     fhir:system [ fhir:v "http://clinicaltrials.gov"^^xsd:anyURI ] ;
     fhir:value [ fhir:v "NCT03240627" ]
  ] ) ; # 
  fhir:title [ fhir:v "Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata."] ; # 
  fhir:status [ fhir:v "completed"] ; # 
  fhir:primaryPurposeType [
     fhir:coding ( [
       fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-prim-purp-type"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "treatment" ]
     ] )
  ] ; # 
  fhir:phase [
     fhir:coding ( [
       fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-phase"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "phase-2-phase-3" ] ;
       fhir:display [ fhir:v "Phase 2/Phase 3" ]
     ] )
  ] ; # 
  fhir:category ( [
     fhir:coding ( [
       fhir:system [ fhir:v "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "C98388" ] ;
       fhir:display [ fhir:v "Interventional Study" ]
     ] )
  ] [
     fhir:coding ( [
       fhir:system [ fhir:v "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "C46079" ] ;
       fhir:display [ fhir:v "Randomized Controlled Clinical Trial" ]
     ] )
  ] [
     fhir:coding ( [
       fhir:system [ fhir:v "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "C15228" ] ;
       fhir:display [ fhir:v "Double Blind Study" ]
     ] )
  ] [
     fhir:coding ( [
       fhir:system [ fhir:v "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "C142743" ] ;
       fhir:display [ fhir:v "Unequal Randomization" ]
     ] )
  ] ) ; # 
  fhir:focus ( [
     fhir:coding ( [
       fhir:system [ fhir:v "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "C1909" ] ;
       fhir:display [ fhir:v "Pharmacologic Substance" ]
     ] )
  ] ) ; # 
  fhir:condition ( [
     fhir:coding ( [
       a sct:68225006 ;
       fhir:system [ fhir:v "http://snomed.info/sct"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "68225006" ] ;
       fhir:display [ fhir:v "Alopecia areata (disorder)" ]
     ] )
  ] ) ; # 
  fhir:location ( [
     fhir:coding ( [
       fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "DE" ] ;
       fhir:display [ fhir:v "Germany" ]
     ] )
  ] [
     fhir:coding ( [
       fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ;
       fhir:code [ fhir:v "FR" ] ;
       fhir:display [ fhir:v "France" ]
     ] )
  ] ) ; # 
  fhir:period [
     fhir:start [ fhir:v "2018-03-01"^^xsd:date ] ;
     fhir:end [ fhir:v "2022-03-17"^^xsd:date ]
  ] ; # 
  fhir:principalInvestigator [
     fhir:link <https://www.vision-zero-oncology.de/fhir/Practitioner/example> ;
     fhir:reference [ fhir:v "Practitioner/example" ]
  ] ; # 
  fhir:site ( [
     fhir:link <https://www.vision-zero-oncology.de/fhir/Organization/Charite-dermatology> ;
     fhir:reference [ fhir:v "Organization/Charite-dermatology" ]
  ] [
     fhir:link <https://www.vision-zero-oncology.de/fhir/Organization/Sabouraud-Center> ;
     fhir:reference [ fhir:v "Organization/Sabouraud-Center" ]
  ] [
     fhir:link <https://www.vision-zero-oncology.de/fhir/Organization/Diagnostic-consulting-center-XXIV-Sofia> ;
     fhir:reference [ fhir:v "Organization/Diagnostic-consulting-center-XXIV-Sofia" ]
  ] [
     fhir:link <https://www.vision-zero-oncology.de/fhir/Organization/SC-Centrul-Medical-Sana-SRL> ;
     fhir:reference [ fhir:v "Organization/SC-Centrul-Medical-Sana-SRL" ]
  ] ) ; # 
  fhir:arm ( [
     fhir:name [ fhir:v "Experimental: LH-8 cutaneous solution" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "C174266" ] ;
         fhir:display [ fhir:v "Investigational Arm" ]
       ] )
     ] ;
     fhir:description [ fhir:v "LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp" ]
  ] [
     fhir:name [ fhir:v "Placebo Comparator: Placebo cutaneous solution" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "C174226" ] ;
         fhir:display [ fhir:v "Control Arm" ]
       ] )
     ] ;
     fhir:description [ fhir:v "Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp" ]
  ] ) ; # 
  fhir:objective ( [
     fhir:name [ fhir:v "Relative change in scalp alopecia areata severity scores (SALT) from baseline value to be assessed after 24 weeks of treatment. [ Time Frame: 24 weeks treatment ] Visual assessment and global standardised scalp photographs for SALT evaluation." ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "primary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Absolute change in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Adverse events [ Time Frame: 48 weeks ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "General physical examination findings, including irritation of eyes and skin [ Time Frame: 24 weeks treatment ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Visual assessment and global standardised scalp photographs for SALT evaluation. [ Time Frame: After 12 and 24 weeks treatment ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Evaluation of duration of treatment effect in responders, measured as relative SALT score changes from Visit 3 (end of treatment) after 12 weeks (Visit 4) and 24 weeks (Visit 5) of treatment-free period. (Visual assessment and global standardised scalp photographs for SALT evaluation.)" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Assessment of treatment effect on hair follicles in non-alopecic areas by quantifying the number of new alopecic areas. [ Time Frame: 24 weeks treatment ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Assessment of the rate of spontaneous hair regrowth. [ Time Frame: For 6-12 months ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Assessment of the rate of spontaneous hair regrowth in placebo treated subjects with alopecia areata active for 6-12 months compared to those with alopecia areata active for more than 12 months. (Visual assessment and global standardised scalp photographs for SALT evaluation)." ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Absolute and relative change from baseline in Children's Dermatology Life Quality Index (CDLQI) scores. [ Time Frame: 48 weeks ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Change in percentage of subjects from baseline by the severity banding CDLQI scores. [ Time Frame: 48 weeks ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Percentages of subjects by EuroQol Five Dimensions Youth Questionnaire (EQ-5D-Y) dimensions and levels at Visits 1-5. [ Time Frame: 48 weeks ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Absolute and relative change of the EQ-Visual Analogue Scale (EQ-VAS) scores from baseline [ Time Frame: 48 weeks ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] [
     fhir:name [ fhir:v "Evaluation of the Paediatric Alopecia Areata Patient Benefit Index (PAAPBI) scores at Visits 1 to 5. [ Time Frame: 48 weeks ]" ] ;
     fhir:type [
       fhir:coding ( [
         fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/research-study-objective-type"^^xsd:anyURI ] ;
         fhir:code [ fhir:v "secondary" ]
       ] )
     ]
  ] ) . # 

# -------------------------------------------------------------------------------------

